Abstract
Current treatment options for the chronic gastrointestinal disorder irritable bowel syndrome (IBS) have long been limited to symptomatic treatments due to lack of pathophysiologic understanding of the syndrome. Within the past 10 years, however, a number of new pharmacological targets have been identified that may aid in the treatment of irritable bowel syndrome. Although only a limited number of new drug entities have entered the market in the past years, many new potential pharmacophores are evolving. Among them, several drugs are in the pipeline that target cholecystokinin or corticotropin-releasing factor receptors, serve as inhibitors for specific tryptophan hydroxylase iso-enzymes, modulate chloride secretion, influence immune responses via monoclonal antibodies or ATPmediated pathways, and even normalize the gastrointestinal microflora via supplementation with probiotics. While new treatments that act via chloride secretion and immune modulation present with favorable outcomes in clinical trials, other novel therapies require further evaluation. This review is intended to provide a synopsis of current and emerging pharmacotherapies for IBS.
Keywords: Irritable bowel syndrome, 5-HT, inflammation, drug development, clinical trials, chronic gastrointestinal disorder, cholecystokinin, corticotropin-releasing factor, monoclonal antibodies, tryptophan hydroxylase, immune modulation, functional bowel disorders, IBS prevalence, tegaserod, polyethylene glycol, Bifidobacterium strains, antispasmodics, antidepressants, tricyclic antidepressants, serotonin reuptake inhibitors, inflammatory bowel disease, IB, occludin, proteasomes, Crohn's disease, interleukin-6, interferon gamma, chemokines, IL-8, IL-6, enteric nervous system, neurotransmitter, acetylcholine, gastrointestinal tract, serotonin reuptake transporter, CNS, dopamine, Gastroenterology, lactose intolerance, Bifidobacterium, Lactobacillus, Streptococcus, cimetropium, pinaverium, otilonium, mebeverine, Dexamethasone, macrolide
Current Pharmaceutical Design
Title: Current Developments for the Diagnosis and Treatment of Irritable Bowel Syndrome
Volume: 16 Issue: 33
Author(s): Oliver Grundmann, Saunjoo L. Yoon and Baharak Moshiree
Affiliation:
Keywords: Irritable bowel syndrome, 5-HT, inflammation, drug development, clinical trials, chronic gastrointestinal disorder, cholecystokinin, corticotropin-releasing factor, monoclonal antibodies, tryptophan hydroxylase, immune modulation, functional bowel disorders, IBS prevalence, tegaserod, polyethylene glycol, Bifidobacterium strains, antispasmodics, antidepressants, tricyclic antidepressants, serotonin reuptake inhibitors, inflammatory bowel disease, IB, occludin, proteasomes, Crohn's disease, interleukin-6, interferon gamma, chemokines, IL-8, IL-6, enteric nervous system, neurotransmitter, acetylcholine, gastrointestinal tract, serotonin reuptake transporter, CNS, dopamine, Gastroenterology, lactose intolerance, Bifidobacterium, Lactobacillus, Streptococcus, cimetropium, pinaverium, otilonium, mebeverine, Dexamethasone, macrolide
Abstract: Current treatment options for the chronic gastrointestinal disorder irritable bowel syndrome (IBS) have long been limited to symptomatic treatments due to lack of pathophysiologic understanding of the syndrome. Within the past 10 years, however, a number of new pharmacological targets have been identified that may aid in the treatment of irritable bowel syndrome. Although only a limited number of new drug entities have entered the market in the past years, many new potential pharmacophores are evolving. Among them, several drugs are in the pipeline that target cholecystokinin or corticotropin-releasing factor receptors, serve as inhibitors for specific tryptophan hydroxylase iso-enzymes, modulate chloride secretion, influence immune responses via monoclonal antibodies or ATPmediated pathways, and even normalize the gastrointestinal microflora via supplementation with probiotics. While new treatments that act via chloride secretion and immune modulation present with favorable outcomes in clinical trials, other novel therapies require further evaluation. This review is intended to provide a synopsis of current and emerging pharmacotherapies for IBS.
Export Options
About this article
Cite this article as:
Grundmann Oliver, L. Yoon Saunjoo and Moshiree Baharak, Current Developments for the Diagnosis and Treatment of Irritable Bowel Syndrome, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079227
DOI https://dx.doi.org/10.2174/138161210794079227 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry The Emerging Role of Bcr-Abl-Induced Cystoskeletal Remodeling in Systemic Persistence of Leukemic Stem Cells
Current Drug Delivery The Use of Growth Factors in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Racial/Ethnic Differences in Symptoms of Posttraumatic Stress Disorder
Current Psychiatry Reviews Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews New Approaches to Structure-Based Discovery of Dengue Protease Inhibitors
Infectious Disorders - Drug Targets Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Postmenopausal Osteoporosis and Aerobic Exercise: A Review of the Literature
Current Rheumatology Reviews Effects of Modafinil on Cognitive Performance and Alertness During Sleep Deprivation
Current Pharmaceutical Design Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Molecular Genetics and Epidemiology of Osteoporosis
Current Pharmacogenomics Approaches to Minimize Infection Risk in Blood Banking and Transfusion Practice
Infectious Disorders - Drug Targets Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design A Partial Failure of Membrane Protein Turnover May Cause Alzheimers Disease: A New Hypothesis
Current Alzheimer Research The Effects of Incretins on Energy Homeostasis: Physiology and Implications for the Treatment of Type 2 Diabetes Mellitus and Obesity
Current Vascular Pharmacology Inhibition of Platelet Adhesion to Collagen as a New Target for Antithrombotic Drugs
Current Drug Targets - Cardiovascular & Hematological Disorders Stem Cell Ageing and Apoptosis
Current Pharmaceutical Design Modulation of Plasma Non Enzimatic Antioxidant Capacity (NEAC) by Plant Foods: the Role of Polyphenol
Current Topics in Medicinal Chemistry Potential Role of IL-18 in the Immunopathogenesis of AIDS, HIVAssociated Lipodystrophy and Related Clinical Conditions
Current HIV Research